YM Biosciences Inc operates in the Pharmaceutical preparations sector. YM BioSciences Inc. (YM) is a drug development company advancing a diverse portfolio of hematology and cancer-related products. The Company is advancing three clinical-stage products: CYT387, an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a potent oral vascular disrupting agent (VDA). The Company also has a library of more than 4,000 compounds identified through internal research conducted at YM BioSciences Australia, which are being evaluated for potential development in various indications. YM has regulatory and clinical trial and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization. In our complete report available for purchase the company is compared to: Isotechnika Pharma Incorporation, Cipher Pharmaceuticals, Inc. and BELLUS Health Incorporation.